Basic Information
| LncRNA/CircRNA Name | HOTAIRM1 |
| Synonyms | NA |
| Region | GRCh38_7:27095647-27100265 |
| Ensemble | ENSG00000233429 |
| Refseq | NR_038366 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | temozolomide | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, etc. |
| Sample | Glioma tissue, U87, LN229, glioma cell lines U373, U251, and T98G and normal human astrocytes |
| Expression Pattern | up-regulated |
| Function Description | HOTAIRM1 expression was associated with clinical and molecular features of glioma: patients with high HOTAIRM1 expression were more likely to be classified as malignant cases, and elevated HOTAIRM1 level was associated with shorter survival time in subgroups stratified by clinical and molecular features. A multivariate Cox regression analysis showed that HOTAIRM1 was an independent prognostic factor for patient outcome. In vitro experiments revealed that HOTAIRM1 knockdown suppressed the malignant behavior of glioma and increased tumor sensitivity to temozolomide. The results of an in silico analysis indicated that HOTAIRM1 promotes the malignancy of glioma by acting as a sponge for microRNA (miR)-129-5p and miR-495-3p. HOTAIRM1 overexpression was also associated with immune activation characterized by enhanced T cellmediated immune and inflammatory responses. |
| Pubmed ID | 31477638 |
| Year | 2019 |
| Title | Long non-coding RNA, HOTAIRM1, promotes glioma malignancy by forming a ceRNA network |
External Links
| Links for HOTAIRM1 | GenBank HGNC NONCODE |
| Links for glioma | OMIM COSMIC |